Last reviewed · How we verify
Raltegravir; Abacavir/Lamivudine
Raltegravir; Abacavir/Lamivudine is a Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Central Institute of Epidemiology, Moscow, Russia. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients. Also known as: Isentress®, Epzicom®.
This combination uses raltegravir (an integrase inhibitor) and abacavir/lamivudine (nucleoside reverse transcriptase inhibitors) to block HIV replication at multiple steps.
This combination uses raltegravir (an integrase inhibitor) and abacavir/lamivudine (nucleoside reverse transcriptase inhibitors) to block HIV replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Raltegravir; Abacavir/Lamivudine |
|---|---|
| Also known as | Isentress®, Epzicom® |
| Sponsor | Central Institute of Epidemiology, Moscow, Russia |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV integrase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir prevents HIV integrase from inserting viral DNA into the host genome, while abacavir and lamivudine inhibit reverse transcriptase to prevent conversion of viral RNA to DNA. Together, these agents from different drug classes provide complementary antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Headache
- Hypersensitivity reaction (abacavir)
- Elevated liver enzymes
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients (PHASE4)
- Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir; Abacavir/Lamivudine CI brief — competitive landscape report
- Raltegravir; Abacavir/Lamivudine updates RSS · CI watch RSS
- Central Institute of Epidemiology, Moscow, Russia portfolio CI
Frequently asked questions about Raltegravir; Abacavir/Lamivudine
What is Raltegravir; Abacavir/Lamivudine?
How does Raltegravir; Abacavir/Lamivudine work?
What is Raltegravir; Abacavir/Lamivudine used for?
Who makes Raltegravir; Abacavir/Lamivudine?
Is Raltegravir; Abacavir/Lamivudine also known as anything else?
What drug class is Raltegravir; Abacavir/Lamivudine in?
What development phase is Raltegravir; Abacavir/Lamivudine in?
What are the side effects of Raltegravir; Abacavir/Lamivudine?
What does Raltegravir; Abacavir/Lamivudine target?
Related
- Drug class: All Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV integrase; HIV reverse transcriptase
- Manufacturer: Central Institute of Epidemiology, Moscow, Russia — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Also known as: Isentress®, Epzicom®
- Compare: Raltegravir; Abacavir/Lamivudine vs similar drugs
- Pricing: Raltegravir; Abacavir/Lamivudine cost, discount & access